Efficacy and Safety of Taeeumjowi-tang in Obese Korean Adults: A Double-Blind, Randomized, and Placebo-Controlled Pilot Trial
Table 4
Safety analyses of TJ001.
Safety parameters
Period
Group
()
Placebo group ()
TJ001 group ()
Mean ± S.D.
()
Mean ± S.D.
()
Blood pressure
Systolic, mmHg
Baseline
0.5360
0.9712
0.9175
0.3607
week 4
0.8620
week 8
0.3451
week 12
0.5248
ANOVA
visit X group interaction:
Diastolic, mmHg
Baseline
0.9167
0.4862
0.5433
0.7461
week 4
0.5852
week 8
0.6966
week 12
0.7933
ANOVA
visit X group interaction:
Pulse, bpm
Baseline
0.0058
0.7718
0.3072
0.0184
week 4
0.9851
week 8
0.3108
week 12
0.1743
ANOVA
visit X group interaction:
AST, IU/L
Baseline
0.0315
0.0003
0.1505
0.0544
week 12
0.9798
ALT, IU/L
Baseline
0.1236
0.0038
0.7464
0.3573
week 12
0.1327
BUN, mg/dL
Baseline
0.1252
0.2556
0.4616
0.7000
week 12
0.8953
Creatinine, mg/dL
Baseline
0.3766
0.6834
0.1547
0.3731
week 12
0.0721
: A value for between-group comparison at each visit and visit X group interaction using ANOVA. (): A value for within-group comparison between baseline and 5th visit by paired -test. (): A value for between-group comparison after 12-week treatment using ANCOVA (baseline as covariate). were considered statistically significant.
